サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1426383

カンジダ症治療薬の世界市場レポート 2024

Candidiasis Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
カンジダ症治療薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

カンジダ症治療薬の市場規模は、今後数年間で着実に成長すると予想されています。 2028年には3.5%の年間複合成長率（CAGR）で36億6,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、精密医療アプローチの採用、世界の抗真菌管理プログラムの実施、カンジダ・オーリスの蔓延の増加、および抗真菌耐性に対する世界の取り組みに起因すると考えられます。さらに、予測期間中に予想される主な動向には、ドラッグデリバリー技術の進歩、遠隔医療と遠隔患者モニタリングの台頭、患者中心のケアへの移行、併用療法の探求、共同調査の取り組みなどが含まれます。これらの動向は、今後数年間でカンジダ症治療薬の情勢を形作ることになるでしょう。

予測される真菌感染症の増加は、次期のカンジダ症治療薬市場の成長を推進する重要な推進力として機能する態勢が整っています。多様な真菌によって引き起こされる真菌感染症は、皮膚、粘膜、内臓などの人体のさまざまな部分に影響を及ぼす可能性があります。個人間の免疫機能低下の事例の増加と真菌感染症の蔓延により、カンジダ症に対する脆弱性が高まっています。このシナリオは、メーカーにとって、根底にある真菌病原体を標的とする、より効果的な特殊な抗真菌薬を開発して供給する機会をもたらします。これらの薬剤は、症状の緩和、合併症の予防、患者の回復、ヘルスケア現場におけるカンジダ感染の封じ込めに役立ち、患者の転帰の向上に貢献します。 2023年7月に疾病管理予防センター（CDC）が示したように、真菌感染症関連の入院は2021年までに合計5万9,212人に急増しました。さらに、入院率は入院1万人当たり2020年の25.0人から2021年には26.8人に上昇しており、年間平均8.5%の増加です。特に、COVID-19コロナウイルス感染症患者の死亡率が顕著に高かったです。したがって、真菌感染症の発生率の増加がカンジダ症治療薬市場の成長を促進すると予想されます。

臨床試験の数の増加により、カンジダ症治療薬市場の成長軌道がさらに加速すると予想されます。臨床試験は、ヒトを対象とした新しい治療法、介入、薬剤、または機器の安全性と有効性を評価することを目的とした極めて重要な調査研究として機能します。 カンジダ症治療薬の領域内で、これらの試験は、潜在的な治療法の安全性と有効性をテストするための体系的かつ厳格な評価プラットフォームを提供することにより、重要な役割を果たします。 2023年5月にClinicalTrials.govが報告したように、登録臨床試験数は2023年には約43万7,533件に急増し、2022年には米国全50州、221か国で登録された研究数が39万9,499件に達しました。この増加は、カンジダ症治療薬の情勢を形作る上で臨床試験の勢いと重要性が高まっていることを強調しています。その結果、臨床試験の数の急増がカンジダ症治療薬市場の成長を促進する重要な要因として浮上しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のカンジダ症治療薬市場、治療タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 薬剤
  • 手術
  • その他の治療
  • 世界のカンジダ症治療薬市場、解剖学的タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 口腔カンジダ症
  • 外陰膣カンジダ症
  • 皮膚カンジダ症
  • 浸潤性カンジダ症
  • 全身性カンジダ症
  • 世界のカンジダ症治療薬市場、投与方法別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 注射
  • 経口
  • 他の投与方法
  • 世界のカンジダ症治療薬市場、患者数別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 大人
  • 小児
  • 世界のカンジダ症治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 在宅ケア
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界のカンジダ症治療薬市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のカンジダ症治療薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • カンジダ症治療薬市場の競合情勢
  • カンジダ症治療薬市場の企業プロファイル
    • Pfizer Inc.
    • Biocon Limited
    • Torrent Pharmaceuticals Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co., Inc.

第31章 その他の大手および革新的な企業

  • AbbVie Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi SA
  • AstraZeneca plc.
  • GSK plc.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • Cipla Inc.
  • Bruker Corporation
  • Lupin Limited
  • Galapagos NV
  • Basilea Pharmaceutica Ltd.
  • WOCKHARDT Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13395

Candidiasis, a fungal infection caused by the overgrowth of Candida species, commonly affects areas such as the mouth, throat, gut, and genital regions. The primary methods of treating candidiasis involve antifungal medications, which can be either topical (applied to the affected area) or oral (ingested), depending on the severity and location of the infection.

Candidiasis therapeutics encompass various treatment approaches, including medication, surgery, and other interventions. Medication involves the use of pharmaceutical drugs to manage or alleviate the condition. The treatments target specific anatomical sites such as oral candidiasis, vulvovaginal candidiasis, cutaneous candidiasis, invasive candidiasis, and systemic candidiasis. These medications can be administered through various routes, including injectable, oral, and others, catering to both adult and pediatric patients. The end-users for these treatments include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The candidiasis therapeutics market research report is one of a series of new reports from The Business Research Company that provides candidiasis therapeutics market statistics, including candidiasis therapeutics industry global market size, regional shares, competitors with a candidiasis therapeutics market share, detailed candidiasis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the candidiasis therapeutics industry. This candidiasis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The candidiasis therapeutics market size has grown steadily in recent years. It will grow from $3.06 billion in 2023 to $3.19 billion in 2024 at a compound annual growth rate (CAGR) of 4.4%. The growth observed in the historic period can be attributed to various factors, including the increased incidence of candidiasis, antibiotic use and resistance, the prevalence of hospital-acquired infections, shifts in fungal resistance patterns, and the impact of awareness and education programs. These factors collectively contributed to the demand for candidiasis therapeutics and the adoption of treatment measures during this period.

The candidiasis therapeutics market size is expected to see steady growth in the next few years. It will grow to $3.66 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The anticipated growth in the forecast period can be attributed to the adoption of precision medicine approaches, the implementation of global antifungal stewardship programs, the increasing prevalence of Candida auris, and global efforts against antifungal resistance. Additionally, major trends expected in the forecast period include advancements in drug delivery technologies, the rise of telemedicine and remote patient monitoring, a shift towards patient-centric care, the exploration of combination therapies, and collaborative research initiatives. These trends are likely to shape the landscape of candidiasis therapeutics in the coming years.

The projected rise in fungal infections is poised to act as a significant driver propelling the growth of the candidiasis therapeutics market in the upcoming period. Fungal infections, caused by diverse fungi, can affect various human body parts, including the skin, mucous membranes, and internal organs. The escalating instances of compromised immune systems among individuals and the growing prevalence of fungal infections heighten the vulnerability to candidiasis. This scenario presents an opportunity for manufacturers to develop and supply specialized, more efficacious antifungal drugs that target underlying fungal pathogens. These drugs aid in symptom alleviation, complications prevention, patient recovery, containment of Candida infections within healthcare settings, and contribute to enhanced patient outcomes. As indicated by the Centers for Disease Control and Prevention (CDC) in July 2023, fungal infection-related hospitalizations surged to a total of 59,212 by 2021. Furthermore, the hospitalization rate escalated from 25.0 in 2020 to 26.8 in 2021 per 10,000 hospitalizations, showing an average annual increase of 8.5%. Notably, fungal hospitalizations exhibited notably high death rates, particularly among COVID-19 patients associated with aspergillosis (57.6%), invasive candidiasis (55.4%), mucormycosis (44.7%), and unspecified mycoses (59.0%). Hence, the escalating incidence of fungal infections is anticipated to drive the growth of the candidiasis therapeutics market.

The increasing number of clinical trials is expected to further fuel the growth trajectory of the candidiasis therapeutics market. Clinical trials serve as pivotal research studies aimed at assessing the safety and efficacy of novel medical treatments, interventions, drugs, or devices in human subjects. Within the domain of candidiasis therapeutics, these trials play a crucial role by offering a systematic and stringent evaluation platform for testing the safety and effectiveness of potential treatments. As reported by ClinicalTrials.gov in May 2023, the number of registered clinical trials surged to around 437,533 in 2023, compared to 399,499 registered studies in 2022 across all 50 states of the United States and spanning 221 countries. This increase underscores the rising momentum and significance of clinical trials in shaping the landscape of candidiasis therapeutics. Consequently, the burgeoning number of clinical trials emerges as a key factor driving the growth of the candidiasis therapeutics market.

The potential side effects associated with antifungal drugs used in treating candidiasis are poised to act as a significant restraint on the growth trajectory of the candidiasis therapeutic market. These medications can lead to adverse effects and potential toxicity when used over prolonged periods, posing a challenge in balancing treatment efficacy with patient safety. For instance, data published by the Korean College of Clinical Pharmacy in September 2022 reported a cumulative total of 901 adverse events linked to antifungal drugs, including oral fluconazole, with 422 specifically associated with itraconazole until April 2022. Furthermore, there were 86 adverse event reports for fluconazole and 46 for itraconazole in 2021. Such findings indicate the considerable impact of side effects attributed to antifungal drugs, which could impede the growth prospects of the candidiasis therapeutic market.

Leading companies operating within the candidiasis therapeutics market are dedicatedly engaged in developing innovative drugs, such as BREXAFEMME (ibrexafungerp tablets), aimed at mitigating the occurrence of recurrent vulvovaginal candidiasis (RVVC) in adult women. BREXAFEMME (ibrexafungerp tablets) constitutes an oral, non-azole medication designed for the treatment of vulvovaginal candidiasis (VVC) and reducing the incidence of recurrent vulvovaginal candidiasis (RVVC), commonly known as chronic yeast infections. For instance, in December 2022, Scynexis Inc., a prominent US-based pharmaceutical company, secured approval from the US Food and Drug Administration (FDA) for BREXAFEMME (ibrexafungerp tablets). The medication targets Candida albicans, the fungus responsible for VVC, by obstructing its growth. Notably, BREXAFEMME is deemed a safe and effective treatment option for vulvovaginal candidiasis (VVC), available solely through prescription, with a recommended dosage of one 150-mg capsule taken orally once daily for a single day. This innovative drug stands as a promising advancement in addressing candidiasis, offering a viable treatment solution while navigating potential concerns related to adverse drug effects.

In May 2023, GSK plc, a prominent UK-based pharmaceutical company, finalized the acquisition of Licensing rights for ibrexafungerp from Scynexism Inc. in a transaction amounting to $90 million. This strategic acquisition grants GSK exclusive rights to further the development and commercialization of ibrexafungerp drugs, a groundbreaking antifungal medication designed for the treatment of vulvovaginal candidiasis (VVC). The acquisition is aimed at expediting the advancement and market availability of ibrexafungerp. Scynexism Inc., a notable US-based pharmaceutical company specializing in therapeutic solutions for fungal diseases, including candidiasis, initially developed this innovative medication.

Major companies operating in the candidiasis therapeutics market report are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.

North America was the largest region in the candidiasis therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the candidiasis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The candidiasis therapeutics market consists of revenues earned by entities by providing services such as medication services, diagnostic tests, consultation services, and medical monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The candidiasis therapeutics market also includes sales of topical creams and ointments, oral medications, medical devices, probiotics, nutritional supplements and antifungal medications that are used in providing these services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Candidiasis Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on candidiasis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for candidiasis therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The candidiasis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Treatment Type: Medication; Surgery; Other Treatments
  • 2) By Anatomy Type: Oral Candidiasis; Vulvovaginal Candidiasis; Cutaneous Candidiasis; Invasive Candidiasis; Systemic Candidiasis
  • 3) By Mode of Administration: Injectable; Oral; Other Mode of Administrations
  • 4) By Patient Population: Adults; Pediatrics
  • 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
  • Companies Mentioned: Pfizer Inc.; Biocon Limited; Torrent Pharmaceuticals Ltd.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Candidiasis Therapeutics Market Characteristics

3. Candidiasis Therapeutics Market Trends And Strategies

4. Candidiasis Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Candidiasis Therapeutics Market Size and Growth

  • 5.1. Global Candidiasis Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Candidiasis Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Candidiasis Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Candidiasis Therapeutics Market Segmentation

  • 6.1. Global Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Medication
  • Surgery
  • Other Treatments
  • 6.2. Global Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral Candidiasis
  • Vulvovaginal Candidiasis
  • Cutaneous Candidiasis
  • Invasive Candidiasis
  • Systemic Candidiasis
  • 6.3. Global Candidiasis Therapeutics Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Injectable
  • Oral
  • Other Mode of Administrations
  • 6.4. Global Candidiasis Therapeutics Market, Segmentation By Patient Population, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Adults
  • Pediatrics
  • 6.5. Global Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users

7. Candidiasis Therapeutics Market Regional And Country Analysis

  • 7.1. Global Candidiasis Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Candidiasis Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Candidiasis Therapeutics Market

  • 8.1. Asia-Pacific Candidiasis Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Candidiasis Therapeutics Market

  • 9.1. China Candidiasis Therapeutics Market Overview
  • 9.2. China Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Candidiasis Therapeutics Market

  • 10.1. India Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Candidiasis Therapeutics Market

  • 11.1. Japan Candidiasis Therapeutics Market Overview
  • 11.2. Japan Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Candidiasis Therapeutics Market

  • 12.1. Australia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Candidiasis Therapeutics Market

  • 13.1. Indonesia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Candidiasis Therapeutics Market

  • 14.1. South Korea Candidiasis Therapeutics Market Overview
  • 14.2. South Korea Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Candidiasis Therapeutics Market

  • 15.1. Western Europe Candidiasis Therapeutics Market Overview
  • 15.2. Western Europe Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Candidiasis Therapeutics Market

  • 16.1. UK Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Candidiasis Therapeutics Market

  • 17.1. Germany Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Candidiasis Therapeutics Market

  • 18.5. France Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.6. France Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.7. France Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Candidiasis Therapeutics Market

  • 19.9. Italy Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Candidiasis Therapeutics Market

  • 20.13. Spain Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Candidiasis Therapeutics Market

  • 21.1. Eastern Europe Candidiasis Therapeutics Market Overview
  • 21.2. Eastern Europe Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Candidiasis Therapeutics Market

  • 22.1. Russia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Candidiasis Therapeutics Market

  • 23.1. North America Candidiasis Therapeutics Market Overview
  • 23.2. North America Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Candidiasis Therapeutics Market

  • 24.1. USA Candidiasis Therapeutics Market Overview
  • 24.2. USA Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Candidiasis Therapeutics Market

  • 25.1. Canada Candidiasis Therapeutics Market Overview
  • 25.2. Canada Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Candidiasis Therapeutics Market

  • 26.1. South America Candidiasis Therapeutics Market Overview
  • 26.2. South America Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Candidiasis Therapeutics Market

  • 27.1. Brazil Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Candidiasis Therapeutics Market

  • 28.1. Middle East Candidiasis Therapeutics Market Overview
  • 28.2. Middle East Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Candidiasis Therapeutics Market

  • 29.1. Africa Candidiasis Therapeutics Market Overview
  • 29.2. Africa Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Candidiasis Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Candidiasis Therapeutics Market Competitive Landscape
  • 30.2. Candidiasis Therapeutics Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Biocon Limited
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Torrent Pharmaceuticals Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. F. Hoffmann-La Roche Ltd.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Merck & Co., Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Candidiasis Therapeutics Market Other Major And Innovative Companies

  • 31.1. AbbVie Inc.
  • 31.2. Bayer AG
  • 31.3. Novartis AG
  • 31.4. Sanofi S.A.
  • 31.5. AstraZeneca plc.
  • 31.6. GSK plc.
  • 31.7. Amgen Inc.
  • 31.8. Teva Pharmaceutical Industries Ltd.
  • 31.9. Astellas Pharma Inc.
  • 31.10. Cipla Inc.
  • 31.11. Bruker Corporation
  • 31.12. Lupin Limited
  • 31.13. Galapagos NV
  • 31.14. Basilea Pharmaceutica Ltd.
  • 31.15. WOCKHARDT Limited

32. Global Candidiasis Therapeutics Market Competitive Benchmarking

33. Global Candidiasis Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Candidiasis Therapeutics Market

35. Candidiasis Therapeutics Market Future Outlook and Potential Analysis

  • 35.1 Candidiasis Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Candidiasis Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Candidiasis Therapeutics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer